Abstracts tagged "ACPA and RANK/RANKL pathway"

Abstract Number: 1327 • 2013 ACR/ARHP Annual Meeting
Autoantibodies To Citrullinated Proteins Associate With Bone Destruction Marker and Are Modulated By First Anti Rheumatic Treatment In Early Rheumatoid Arthritis
Aase Haj Hensvold¹, Vijay Joshua¹, Saedis Saevarsdottir², Michaela Larkin², Lena Israelsson², Ferhan Qureshi³, Per-Johan Jakobsson², Nadine A. Defranoux⁴, Lars Klareskog², Vivianne Malmström⁵ and Anca I Catrina², ¹Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Crescendo Bioscience, Inc., South San Francisco, CA, ⁴Crescendo Bioscience Inc., South San Francisco, CA, ⁵Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Antibodies against citrullinated proteins (especially anti citrullinated-vimentin antibodies) and high levels of RANKL have been linked to altered bone metabolism in early RA. We…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.